Trade Moderna Inc ^MRNA

FDA Reopens Review Of Moderna Flu Shot And Shifts Investor Focus

How Trump's FDA is breaking his promise to America's patients

Head to Head Analysis: Moderna (NASDAQ:MRNA) & Genprex (NASDAQ:GNPX) - Daily Political

Aberdeen Group plc Reduces Stock Holdings in Moderna, Inc. $MRNA

Is Moderna (MRNA) Pricing Reflect Its mRNA Pipeline Potential After 62% Year To Date Rally

Moderna's vaccine ambitions run into a wall of 'anti-science' scepticism

500,000 Shares in Moderna, Inc. $MRNA Bought by Telemark Asset Management LLC

Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.

NEOS Investment Management LLC Boosts Holdings in Moderna, Inc. $MRNA - Daily Political

FDA agrees to review Moderna's mRNA flu vaccine following initial refusal - NaturalNews.com

Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020

BioNTech fires shots at Moderna's next-generation vaccine | Americas | Life Sciences Intellectual Property Review

GSA Capital Partners LLP Boosts Stock Position in Moderna, Inc. $MRNA

BioNTech Takes Legal Action Against Moderna for COVID Vaccine Patent Infringement, ETPharma

Moderna (NASDAQ:MRNA) Shares Up 7.1% - Time to Buy?

Healthy Returns: FDA chief Marty Makary on GLP-1 copies, vaccines, China

Moderna (MRNA) Valuation Check After Recent Share Price Surge And Pipeline Expectations

Business NewsLine, Feb. 19, 2026

Thrivent Financial for Lutherans Has $345,000 Stake in Moderna, Inc. $MRNA

Moderna's Flu Vaccine Reapplication Accepted by US FDA: What You Need to Know, ETPharma

Dow Jones Top Company Headlines at 7 PM ET: FDA Reverses Course and Will Now Review Moderna's Flu Shot | Nvidia ... | Morningstar

FDA's abrupt flip-flop on Moderna's mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

Moderna Loses 2 Defenses In Patent Fight

Dow Jones Top Company Headlines at 5 PM ET: FDA Reverses Course and Will Now Review Moderna's Flu Shot | Nvidia ... | Morningstar

Stock market today: Dow, S&P 500 gain for 3rd straight day, Nasdaq jumps as traders brush aside AI worries

Why Moderna (MRNA) Stock Is Trading Up Today

Stock market today: Dow, S&P 500, Nasdaq rise as AI worries recede, Fed minutes released

In reversal, US FDA will review Moderna's flu vaccine application

Moderna (NASDAQ:MRNA) Shares Gap Up Following Analyst Upgrade

Moderna stock surges as FDA reverses course, agrees to review new flu shot

FDA agrees to review Moderna's flu shot application after refusal

FDA reverses course and will review Moderna's mRNA-based flu shot

What Moderna (MRNA)'s Flu Filing Setback and 2025 Loss Mean For Its Regulatory Path - Simply Wall St News

Moderna got the FDA to change its mind, and review its flu vaccine after some concessions | Morningstar

Sensei stock soars on buyout of Faeth for PI3K/AKT/mTOR prospect | BioWorld

US FDA reverses course, will review Moderna's revised flu vaccine application

Berkshire reduces Apple stake, FDA to review Moderna vaccine

FDA Reverses Decision and Agrees To Review Moderna's Flu Vaccine

FDA reverses decision not to review Moderna's new flu vaccine

Flu shot: FDA will review Moderna's mRNA vaccine, company says | CNN

U.S. FDA reverses course, will review Moderna's modified flu vaccine application

Moderna combo vaccine: Flu-COVID jab shows strong trial results

Moderna, Inc. (NASDAQ:MRNA) Receives $28.77 Consensus Target Price from Analysts - Markets Daily

Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

Rhumbline Advisers Purchases 39,229 Shares of Moderna, Inc. $MRNA

Moderna's flu vaccine back in play as FDA shifts course on review | BioWorld

Moderna Loses Key Covid-Shot Patent Defenses Before Jury Trial

FDA reverses course, will review Moderna's new mRNA flu vaccine

Lack of federal support means vaccine makers are investing less in R&D

Moderna (NASDAQ:MRNA) Given New $41.00 Price Target at The Goldman Sachs Group - Markets Daily

Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90

Editorial: Letting disease win -- FDA's dangerous refusal of Moderna's new mRNA flu vaccine | Op Eds | ArcaMax Publishing

Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON) | Markets Insider

Biotech Stocks To Watch Now - February 16th - Stock Observer

Promising Biotech Stocks To Add to Your Watchlist - February 15th - Daily Political

Lisa Jarvis: Moderna's flu shot ordeal hurts innovation -- and public health | Op Eds | ArcaMax Publishing

Moderna Surpasses Revenue Expectations Driven by Strong COVID Vaccine Sales, ETPharma

Dow Jones Top Company Headlines at 7 PM ET: Anthropic Adds New Board Member as It Eyes IPO | Moderna ... | Morningstar

Dow Jones Top Company Headlines at 5 PM ET: Anthropic Adds New Board Member as It Eyes IPO | Moderna ... | Morningstar

Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend

Stock market today: Dow, S&P 500, Nasdaq gains fizzle to cap week of sharp losses as AI fears grow

Dow Jones Top Company Headlines at 3 PM ET: Anthropic Adds New Board Member as It Eyes IPO | Moderna ... | Morningstar

Traders Buy High Volume of Call Options on Moderna (NASDAQ:MRNA) - Markets Daily

Stock market today: S&P 500, Dow, Nasdaq rise as CPI inflation cools, but weekly losses loom

Stock Traders Purchase High Volume of Moderna Call Options (NASDAQ:MRNA)

Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial ...

Moderna's mRNA Technology Has Potential Across Vaccines, Oncology, and Rare Diseases | Morningstar

Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results, Beats Estimates By $0.68 EPS

Dow Jones Top Company Headlines at 1 PM ET: Anthropic Adds New Board Member as It Eyes IPO | Moderna ... | Morningstar

Stock market today: S&P 500, Dow, Nasdaq rise after CPI inflation cools more than expected

Pharma and biotech are back, says UBS' Michael Yee

Moderna beats Q4 revenue estimate - BNN Bloomberg

Earnings live: Moderna stock pops on revenue growth, Rivian surges, Applied Materials jumps

Dow Jones Top Company Headlines at 11 AM ET: Anthropic Adds New Board Member as It Eyes IPO | Moderna ... | Morningstar

Moderna (NASDAQ:MRNA) Trading 7.2% Higher Following Better-Than-Expected Earnings

Moderna Q4 Earnings Call Highlights | MarketBeat

Dow Jones Top Company Headlines at 9 AM ET: Moderna Narrows Loss, Reiterates 10% Revenue Growth Target | Dubai ... | Morningstar

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna Just Crushed Estimates While Everyone Was Looking the Other Way

Why did the U.S. FDA decline to review the new mRNA influenza vaccine? - The Hindu

Moderna beats quarterly revenue estimates on resilient sales of COVID shot

Moderna Q4 Earnings Call Highlights - Stock Observer

FDA Refuses to Review Moderna's New Flu Shot

FDA rejects Moderna's mRNA flu vaccine application - for reasons with no basis in the law - Yahoo News Canada

Dassault Systèmes SE (OTC:DASTY) Q4 2025 Earnings Call Transcript

Biotech Turnaround: How Moderna Went From Revenue Collapse to YTD Rally Leader

US FDA declines Moderna flu vaccine review amid vaccine guidance rollback | Health News | Al Jazeera

FDA defends its decision to not review Moderna's mRNA flu shot

FDA Refuses To Review Moderna's Application For Experimental Flu Shot | ZeroHedge

Barclays Starts Moderna, Inc. (MRNA) Neutral as Biotech Outlook Improves

Stocks making the biggest moves midday: ACHC, VRT, MRNA, U, GNRC

FDA refuses to review Moderna flu shot in surprise setback

Moderna dips on flu vaccine RTF letter | BioWorld

Moderna (MRNA) Stock Falls 9% After FDA Rejects Flu Vaccine Application